Sorrento Therapeutics Inc.'s majority owned subsidiary Scilex Pharmaceuticals Inc. will merge with Semnur Pharmaceuticals, creating a new company, Scilex Holding Co., focusing on non-opioid pain management. Scilex's lead product is Ztlido, a lidocaine topical system, and Semnur's lead compound is a non-opioid corticosteroid gel that's in phase III pivotal studies. Sorrento said the merger positions Scilex Holding to become "a global leader in non-opioid pain management."